Einträge von Scharl, A. auf dem Publikationsserver

Ortmann, Olaf , Blohmer, J.-U., Sibert, N. T., Brucker, S., Janni, W., Wöckel, A., Scharl, A., Dieng, S., Ferencz, J., Inwald, E. C., Wesselmann, S., Kowalski, C., Denisjuk, E., Csorba, R., Rezek, D., Peschel, S., Denschlag, D., Schad, F., Dieterle, D., Lex, B., Rieger, L., Flock, F., Cramer, A., Strittmatter, H.-J., Bettscheider, J., Lindner, C., Stefek, A., Pauker, W., Hönig, A., Schrauder, M., Seeger, D., Kleine-Tebbe, A., Bleimehl, A., Groh, U., Gebauer, G., Vollert, H.-W., Zorr, A., Friedmann, W., Krabisch, P., Fritz, S., Schwämmle, A., Lucke, W., Schmatloch, S., Heyl, W., Deuschle, P., Arfsten, M., Scheler, P., Bleimehl, A., Ruf-Dördelmann, A., Brückner, B., Bauer, L., Koch, M., Monner, J., Nixdorf, A., Merte, A., Beldermann, F., Blohmer, J.-U., Janni, W., Felberbaum, R., De Wilde, R. L., Bolkenius, P., Lebrecht, A., Solomayer, E.-F., Hartmann, S. und Hartkopf, A. (2022) Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers. Journal of Cancer Research and Clinical Oncology.

Papathemelis, Thomas , Scharl, S., Kronberger, K., Gerken, M., Scharl, A., Pauer, A. und Klinkhammer-Schalke, M. (2017) Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis. Journal of Cancer Research and Clinical Oncology 143 (12), S. 2555-2562. Volltext nicht vorhanden.

Heidemann, E., Stoeger, H., Souchon, R., Hirschmann, W.-D., Bodenstein, H., Oberhoff, C., Fischer, J. T., Schulze, M., Clemens, M., Andreesen, Reinhard, Mahlke, M., König, M., Scharl, A., Fehnle, K. und Kaufmann, M. (2002) Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 13 (11), S. 1717-29. Volltext nicht vorhanden.

Heidemann, E., Stoeger, H., Souchon, R., Hirschmann, W.-D., Bodenstein, H., Oberhoff, C., Fischer, J.T., Schulze, M., Clemens, M., Andreesen, R., Mahlke, M., König, M., Scharl, A., Fehnle, K. und Kaufmann, M. (2002) Is first-line single-agent mitoxantrone in the treatment ofhigh-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Annals of Oncology 13 (11), S. 1717-1729. Volltext nicht vorhanden.